Sermorelin

Name: Sermorelin
Brand: Peptific
SKU: SERMORELIN-STANDARD

Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.

Currently unavailable

This product is listed for research reference. It is not currently available for ordering. Live alternatives from the same research category are shown below.

Research reference only

This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.

Notify me when available

✓HPLC purity tested
✓COA per lot, on request
✓Lyophilized, sealed
✓US shipping, tracked

First FDA-approved GHRH peptide — longest regulatory and clinical research history of any synthetic GHRH compound
Full GHRH receptor agonism via the biologically active N-terminal 29-amino-acid sequence
Maintains intact somatostatin feedback and IGF-1 counter-regulation — physiologically patterned GH pulses
~10–20 minute half-life enables acute GH pulse kinetics research with clean on/off dynamics
Most historically documented synthetic GHRH in preclinical literature — decades of published animal and human data

Need the COA before you order? Request it here.

In your order

What ships when you order Sermorelin

Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.

The Peptific standard

Why researchers buy from Peptific instead of grey-market vendors

Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.

Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.

Available now

Live alternatives from this research category

These products from the same research category are currently available for ordering.

How it works

The Sermorelin mechanism

Sermorelin binds GHRH receptors on pituitary somatotropes via the active N-terminal sequence of native GHRH, stimulating pulsatile GH release through cAMP signaling. The endogenous feedback axis (somatostatin, IGF-1) remains intact, producing physiologically patterned GH pulses. Half-life ~10–20 minutes in vivo; short active window defines its research utility in acute GH pulse studies.

Compound profile

Class: Synthetic GHRH analog (GHRH(1-29)NH2)
Amino acids: 29
Molecular weight: ~3,358 Da
Half-life: ~10–20 minutes in vivo
CAS: 86168-78-7
Clinical status: FDA-approved (Geref) for pediatric GH deficiency — discontinued commercially
Research category: GHRH receptor pharmacology, GH axis, GH pulse research
Storage: Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days

Product definition

What is Sermorelin?

Sermorelin is a 29-amino-acid synthetic GHRH(1-29) analog — the first FDA-approved GHRH peptide (Geref), with the longest published research history of any synthetic GHRH compound.

Sermorelin (also designated GHRH(1-29)NH2) is the C-terminally amidated 29-amino-acid N-terminal fragment of the 44-amino-acid endogenous GHRH. Studies dating to the 1980s established that GHRH(1-29) retains full receptor binding and GH-stimulating potency relative to the full-length peptide — the C-terminal residues beyond position 29 contribute little to biological activity. The FDA approved sermorelin (as Geref, Serono) for GH deficiency in pediatric patients, establishing the first regulatory approval for any synthetic GHRH compound. This regulatory dataset provides human pharmacokinetic characterization (dose-response, GH AUC, IGF-1 normalization) that constitutes the foundational GHRH analog research literature. Sermorelin's short half-life distinguishes it from tesamorelin (trans-3-hexenoic acid N-terminal modification, ~26 minutes) and CJC-1295 variants (30 minutes to 6–8 days), positioning sermorelin as the first-generation reference compound for short-duration GHRH receptor activation protocols.

Research audience

Who studies Sermorelin?

Sermorelin is used by researchers studying GHRH receptor pharmacology, GH pulse physiology, pituitary somatotrope function, GH deficiency models, and GH axis response to intervention. It is particularly relevant for labs requiring a historically grounded reference GHRH compound with published human pharmacokinetic data.

Research context

What does the preclinical literature say about Sermorelin?

Sermorelin's research history predates the modern synthetic peptide research supply market. Published human studies from the 1980s and 1990s characterized its dose-response relationship for GH stimulation, its utility in GH deficiency testing (GH stimulation test), and its effects on body composition in GH-deficient children. This long publication record makes sermorelin uniquely interpretable — there is decades of experimental context for its pharmacological effects. In animal model research, sermorelin has been studied for age-related GH secretion decline (somatopause), GH axis response to chronic administration, and pituitary somatotrope sensitivity. The preserved feedback axis under sermorelin administration (versus direct GH supplementation) has made it a useful model for studying the regulated GH secretion system rather than simply supplying GH exogenously. For comparative pharmacology research, sermorelin serves as the baseline against which newer GHRH analogs are evaluated. The improvements from sermorelin to tesamorelin (DPP-IV resistance), CJC-1295 Without DAC (four protective substitutions), and CJC-1295 With DAC (albumin binding, 6–8 day half-life) each represent incremental pharmacokinetic advances measured against the sermorelin baseline.

Common questions

How does sermorelin compare to CJC-1295 Without DAC?

Both are GHRH analogs that bind the GHRH receptor and produce pulsatile GH release. Sermorelin is native GHRH(1-29) — susceptible to DPP-IV cleavage, half-life ~10–20 min. CJC-1295 Without DAC (MOD GRF 1-29) has four protective amino acid substitutions that confer DPP-IV resistance and extend half-life to ~30 minutes. For research requiring the historically documented first-generation GHRH reference compound, sermorelin is appropriate. For protocols requiring longer active windows with the same receptor mechanism, CJC-1295 Without DAC is the better choice.

Is sermorelin still commercially available as a pharmaceutical?

Geref (Serono) was voluntarily discontinued from the US market in 2008 for commercial reasons unrelated to safety. Sermorelin remains available as a research compound, and some compounding pharmacies in the US have included it in compounded preparations. Its FDA approval history and the published pharmacokinetic data from the approved product period remain in the research literature.

What storage conditions does sermorelin require?

Lyophilized sermorelin is stable at −20°C. Reconstituted, store at 2–8°C and use within 14 days — sermorelin's short peptide without protective modifications has slightly lower solution stability than protected analogs like CJC-1295 Without DAC. Avoid repeated freeze-thaw of reconstituted material.